Norepinephrine Transporter-Targeted Cancer Theranostics-New Horizons.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39570057.
- Also identified by DOI 10.1097/RLU.0000000000005567.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the evolving landscape of precision oncology, this review delineates the role of radiopharmaceuticals targeting the norepinephrine transporter (NET), with a particular focus on the current clinical application of 123 I-MIBG diagnostic imaging and 131 I-MIBG therapeutics, in particular for pheochromocytoma, neuroblastoma, or paraganglioma. We will also highlight recently introduced 18 F-labeled NET targeting imaging radiotracers, which would offer unparalleled resolution, enhanced tumor localization, and staging properties. Complementing these novel second-generation PET agents in a theranostic approach, astatine-211 meta-astatobenzylguanidine ( 211 At-MABG) would leverage the advantages of alpha-particles to selectively target and eradicate NET-expressing tumor cells with minimal off-target effects.
Medical subject headings
- Norepinephrine Plasma Membrane Transport Proteins
- Neoplasms